CA2371216A1 - Pseudotype de vecteur retroviral destine a la therapie genique du cancer - Google Patents

Pseudotype de vecteur retroviral destine a la therapie genique du cancer Download PDF

Info

Publication number
CA2371216A1
CA2371216A1 CA002371216A CA2371216A CA2371216A1 CA 2371216 A1 CA2371216 A1 CA 2371216A1 CA 002371216 A CA002371216 A CA 002371216A CA 2371216 A CA2371216 A CA 2371216A CA 2371216 A1 CA2371216 A1 CA 2371216A1
Authority
CA
Canada
Prior art keywords
cells
retroviral
expression vector
tumor
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371216A
Other languages
English (en)
Inventor
Jacques Galipeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371216A1 publication Critical patent/CA2371216A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des vecteurs d'expression rétroviraux et notamment des pseudotypes de vecteurs rétroviraux destinés à la thérapie génique du cancer. Le ciblage direct "in vivo" des tumeurs avec des vecteurs viraux "suicidaires" est limité par l'inefficacité du transfert de gènes et par le transfert non discriminé d'un gène conditionnellement toxique vers des tissus environnants non malins. L'utilisation de rétrovirus dont on a obtenu le pseudotype avec une protéine G du virus de la stomatite vésiculaire (VSVG) peut apporter une solution au problème. Ces particules rétrovirales se distinguent, dans le cas des rétrovirus murins standard, par leur tropisme très large et par leur capacité d'être concentrés par ultracentrifugation sans perdre leur activité. On peut utiliser un rétrovecteur dont on a obtenu le pseudotype avec VSVG pour un apport in vivo efficace de la thimidine kinase (TK) du virus herpès simplex. Selon cette invention, on a construit un vecteur rétroviral cistronique qui exprime la TK et la protéine verte fluorescente (pTKiGFP).
CA002371216A 1999-04-23 2000-04-20 Pseudotype de vecteur retroviral destine a la therapie genique du cancer Abandoned CA2371216A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13068099P 1999-04-23 1999-04-23
US60/130,680 1999-04-23
PCT/CA2000/000445 WO2000065034A2 (fr) 1999-04-23 2000-04-20 Pseudotype de vecteur retroviral destine a la therapie genique du cancer

Publications (1)

Publication Number Publication Date
CA2371216A1 true CA2371216A1 (fr) 2000-11-02

Family

ID=22445832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371216A Abandoned CA2371216A1 (fr) 1999-04-23 2000-04-20 Pseudotype de vecteur retroviral destine a la therapie genique du cancer

Country Status (4)

Country Link
EP (1) EP1173551A2 (fr)
AU (1) AU4096100A (fr)
CA (1) CA2371216A1 (fr)
WO (1) WO2000065034A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002310969A1 (en) * 2001-03-21 2002-10-03 Ipf Pharmaceuticals Gmbh Reporter virus comprising heterologous envelope proteins
EP1446479B1 (fr) * 2001-09-29 2012-08-15 Chae-Ok Yun Adenovirus recombinant a effet therapeutique ameliore et composition pharmaceutique comprenant ledit adenovirus recombinant
WO2005038035A2 (fr) * 2003-10-15 2005-04-28 University Of Iowa Research Foundation Procedes de production et d'utilisation de retrovirus pseudotypes in vivo
CN102978239A (zh) * 2012-12-12 2013-03-20 广西壮族自治区水产研究所 两个对虾新型表达载体构建方法
WO2020043765A1 (fr) * 2018-08-30 2020-03-05 Miltenyi Biotec Gmbh Lignée cellulaire d'encapsidation négative ldlr pour la production de particules de vecteur rétroviral pseudotypées vsv-g ou de particules virales correspondantes
CN113717990B (zh) * 2021-08-30 2023-08-15 武汉大学 一种基于双报告基因的新型水泡性口炎假病毒系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
DE69533959D1 (de) * 1994-08-17 2005-03-03 Genetic Therapy Inc Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
WO1999004026A2 (fr) * 1997-07-18 1999-01-28 Chiron Corporation Vecteurs lentiviraux

Also Published As

Publication number Publication date
AU4096100A (en) 2000-11-10
WO2000065034A3 (fr) 2001-01-25
WO2000065034A2 (fr) 2000-11-02
EP1173551A2 (fr) 2002-01-23

Similar Documents

Publication Publication Date Title
Galipeau et al. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer
Paquin et al. Retrovector encoding a green fluorescent protein–herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications
Boesen et al. Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr 1 gene
AU2002303247B2 (en) Chemotherapeutic induction of Egr-1 promoter activity
AU2002303247A1 (en) Chemotherapeutic induction of Egr-1 promoter activity
CA2371216A1 (fr) Pseudotype de vecteur retroviral destine a la therapie genique du cancer
JPH09504518A (ja) 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療
Grez et al. Gene therapy of chronic granulomatous disease
Rainov et al. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma
WO1999026480A1 (fr) Vecteurs de therapie genique anti-angiogenique et leurs applications dans le cadre du traitement d'affections liees a l'angiogenese
CAO et al. Construction of retroviral vectors to induce strong hepatoma cell‐specific expression of cytokine genes
Vrionis et al. A more potent bystander cytocidal effect elicited by tumor cells expressing the herpes simplex virus—thymidine kinase gene than by fibroblast virus—producer cells in vitro
EP0973902A1 (fr) Methodes et compositions de concentration de radio-isotopes
AU2004252010A1 (en) Method for transplanting lymphohematopoietic cells into mammal
US20030031650A1 (en) Drug inducible system and use thereof
EP1045920A1 (fr) Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique
US6537541B1 (en) Implantation of HSV-TK retrovirus producer cells to destroy glioma
Burt et al. Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes
EP1268812A2 (fr) Vecteurs pour therapie genique
Hermann Improved therapeutic efficacy of cancer gene therapy using Retroviral Replicating Vectors designed for multiple transgene transduction
Roth et al. Local and systemic pro-apoptotic gene replacement for cancer
Rozov et al. Selection of genetically modified hematopoietic cells in vitro and in vivo using alkylating agent lysomustine
Unger Enriching suicide gene bearing tumor cells in vivo for an increased bystander effect: a novel strategy for cancer gene therapy
CA2047363C (fr) Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs
Hermann Improved Therapeutic Efficacy of Cancer Gene Therapy using RRVs Designed for Multiple Transgene Transduction

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead